GRAIL, Inc. (GRAL) Stock

GRAIL, Inc. (GRAL) is a Healthcare stock trading at $63.69 (as of 2026-06-18), with a market capitalization of $3.08B and a trailing P/E of -7.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

GRAIL, Inc. is a biotechnology company developing technologies for early cancer detection. Its products include a blood-based screening test (Galleri) for asymptomatic individuals over 50 and a diagnostic aid (DAC) to support cancer testing when cancer is clinically suspected, along with development of additional post-diagnostic tests.

Valuation — source: SEC EDGAR (first-party)
Price	$63.69
Market Cap	$3.08B
P/E Ratio	-7.0
EV / EBITDA	-5.7
Price / Book	1.23
Price / Sales	19.70
DCF Value (model)	$-118.21
DCF Upside vs Price	-285.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$147.17M
Net Margin	-277.5%
Return on Equity	-15.8%
Current Ratio	11.74
Revenue Growth (YoY)	17.2%
EPS Growth (YoY)	-82.5%
FCF Growth (YoY)	-48.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-0.56 (distress)

Valuation vs Sector & Industry
Stock P/E	-7.0
Sector P/E (Healthcare)	21.0
Industry P/E (Healthcare Services)	23.0
vs Sector	-133.2%
vs Industry	-130.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BAKER BROS. ADVISORS LP ($208.20M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Healthcare Services
CEO	Robert Ragusa
Employees	1,000
Country	US
IPO Date	2024-06-12

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.